Asia Pacific Obesity Treatment Market
Market Size in USD Billion
CAGR :
% 
USD
5.09 Million
USD
16.72 Million
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 5.09 Million |
 Market Size (Forecast Year) |
USD 16.72 Million |
 CAGR |
% |
| Major Markets Players |
Asia Pacific Obesity Treatment Market Segmentation, By Treatment Type (Pharmacological Treatments (Anti-obesity Drugs), Bariatric Surgery, Behavioral & Lifestyle Therapy, Non-Invasive/ Endoscopic Procedures, and Medical Devices & Technologies), Age Group (Adult Obesity Treatment, Geriatric Obesity Treatment, and Pediatric Obesity Treatment), Distribution Channel (Online Pharmacies, Retail Pharmacies, Weight Management Clinics, Hospital Pharmacies, and Wellness & Fitness Centers), Patient Type (Class III, Class II, and Class I) - Industry Trends and Forecast to 2032
Asia Pacific Obesity Treatment Market Size
- The Asia Pacific Obesity Treatment Market was valued at USD 5.09 million in 2024 and is expected to reach USD 16.72 Million by 2032
- During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 16.0 % primarily driven by the increasing prevalence of obesity
- This growth is driven by factors such as innovations in anti-obesity medications, growth in bariatric and metabolic surgeries. In addition, integration of digital health solutions in obesity treatment
Asia Pacific Obesity Treatment Market Analysis
- Obesity is a chronic medical condition characterized by excessive fat accumulation, increasing the risk of severe health complications such as cardiovascular diseases, type 2 diabetes, hypertension, and certain cancers
- Treatment options range from lifestyle modifications, pharmacotherapy, and medical devices to bariatric surgery, aiming to achieve sustainable weight loss and improve overall health outcomes
- The Asia- Pacific obesity treatment market is driven by the rising prevalence of obesity due to sedentary lifestyles, unhealthy dietary habits, and genetic predisposition. Pharmacological interventions, including GLP-1 receptor agonists and appetite suppressants, play a crucial role in weight management, alongside behavioral therapy and lifestyle changes. Bariatric surgeries, such as gastric bypass and sleeve gastrectomy, are also gaining traction as effective long-term solutions for severe obesity
- The increasing demand for minimally invasive procedures and innovative anti-obesity medications is further propelling market growth
- North America remains a dominant region in the Asia- Pacific obesity treatment market, supported by well-established healthcare infrastructure, high obesity rates, and continuous research in weight management solutions
- For instance, the U.S. leads in the adoption of GLP-1 receptor agonists like semaglutide and liraglutide, along with advancements in non-invasive medical devices designed for weight loss
- With a growing emphasis on obesity management and preventive healthcare, the Asia- Pacific market is witnessing significant investments in novel therapies, medical technologies, and patient-centric solutions, driving overall industry expansion
Report Scope and Obesity Treatment Market Segmentation
|
Attributes |
Asia- Pacific Obesity Treatment Market Key Market Insights |
|
Segments Covered |
|
|
Countries Covered |
Asia- Pacific
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework. |
Asia- Pacific Obesity Treatment Market Trends.
“Rising Adoption of Digital and AI-Driven Weight Management Solutions”
- A key trend in the global obesity treatment market is the increasing adoption of digital and AI-driven weight management solutions
- These innovative technologies enhance obesity management by providing personalized treatment plans, real-time monitoring, and data-driven insights to optimize weight loss strategies
- For instance, AI-powered mobile applications and wearable devices track physical activity, caloric intake, and metabolic rates, offering tailored recommendations to improve adherence and outcomes
- Telemedicine platforms and virtual coaching further support patients by providing remote consultations, behavioral counseling, and medication management, leading to more effective and sustainable weight loss
- This trend is revolutionizing obesity care by improving patient engagement, enhancing long-term treatment success, and driving demand for digital health solutions in the obesity treatment market
Global Obesity Treatment Market Dynamics
Driver
“Increasing Prevalence of Obesity”
- The obesity epidemic is escalating due to sedentary lifestyles, poor dietary habits, and genetic predisposition, leading to a sharp increase in obesity-related health complications such as diabetes, cardiovascular diseases, and hypertension
- Urbanization and technological advancements have contributed to reduced physical activity, while widespread consumption of processed and high-calorie foods has further fueled weight gain
- Genetic factors also play a significant role, with many individuals being predisposed to metabolic disorders that contribute to obesity. As obesity rates continue to surge, the demand for effective treatment solutions, including pharmacological therapies, bariatric surgeries, and medically supervised weight management programs, is rising significantly
For instance,
- In March 2024, as per the information provided by WHO, the Europe obesity epidemic is escalating, with 1 in 8 people living with obesity in 2022. Adult obesity has doubled since 1990, and adolescent obesity has quadrupled. Over 2.5 billion adults were overweight, including 890 million with obesity. Rising obesity rates contribute to increased risks of diabetes, heart disease, and cancer, fueling demand for effective treatments and driving market growth
- In September 2024, as highlighted by the Centers for Disease Control and Prevention, between August 2021 and August 2023, 40.3% of adults were living with obesity, with 39.2% of men and 41.3% of women affected. The highest prevalence was among adults aged 40–59 (46.4%), followed by 20–39 (35.5%) and 60+ (38.9%). The increasing obesity burden is expected to drive demand for effective obesity treatments
- In 2024, as mentioned by World Obesity Atlas, by 2035, 79% of overweight and obese adults and 88% of overweight and obese children will reside in Low- and Middle-Income Countries (LMICs). The number of adults with obesity is projected to increase from 0.81 billion in 2020 to 1.53 billion in 2035. This rising prevalence is increasing the demand for obesity treatment solutions, driving market growth
- This growing patient burden is driving healthcare providers, pharmaceutical companies, and wellness programs to expand their offerings, making the rising prevalence of obesity a key driver for the Europe obesity treatment market
Opportunity
“Increasing Prevalence of Lifestyle Related Diseases”
- As more individuals seek to manage their weight and mitigate associated health risks, pharmaceutical companies and healthcare providers are incentivized to innovate and expand their offerings
- This trend fosters the development of new medications, surgical options, and comprehensive lifestyle programs tailored to diverse patient needs
For instance,
- In May 2023, NCBI stated that it is estimated that more than 1 billion people will be living with obesity by 2030.1 The higher rates of obesity-associated mortality and comorbidities, such as diabetes, cardiovascular disease, chronic kidney disease, and several types of cancer, are equally staggering, with an average of 5 million deaths and 160 million disability-adjusted life-years
- In June 2023, according to an article published by Acta Pharmaceutica Sinica B, obesity strongly contributes to the development of cancer, cardiovascular diseases, type 2 diabetes, liver diseases and other disorders
- In April 2021, according to an article published in the American Heart Association Journals, Obesity contributes directly to incident cardiovascular risk factors, including dyslipidemia, type 2 diabetes, hypertension, and sleep disorders. Obesity also leads to the development of cardiovascular disease and cardiovascular disease mortality independently of other cardiovascular risk factors
- In April 2023, a study by MoneyControl outlined that India has experienced a massive spike in lifestyle diseases, including an increase in the prevalence of early risk factors like obesity and cholesterol irregularities
- In addition, heightened awareness regarding the health consequences of obesity encourages proactive health management among consumers. With supportive initiatives from governments and health organizations promoting healthier lifestyles, the obesity treatment market is poised for substantial growth
- This momentum attracts investment and boosts research and development efforts, paving the way for a wide range of therapeutic interventions to meet the needs of an expanding patient population
Restraint/Challenge
“LONG-TERM FOLLOW-UPS ASSOCIATED WITH OBESITY TREATMENT”
- Long-term follow-ups associated with obesity treatment primarily due to the complexity and resource intensiveness of such programs often requires continuous monitoring and support to ensure sustained weight loss and management, which can include regular consultations, nutritional guidance, and behavioral therapy
- These long-term commitments burden healthcare systems and pose logistical challenges for both patients and providers, leading to potential gaps in care and inconsistent treatment adherence
For instance,
- In December 2022, as per AJMC, managing obesity requires the ongoing partnership of a committed patient and informed clinicians. Managing obesity requires the ongoing partnership of a committed patient and informed clinicians
- In September 2022, JAMA Network reported that, in research carried for 175 patients, 94 (53.7%) had weight loss of at least 5% and 26 (14.9%) had weight loss of 10% or more at 3 months. Of 102 patients who were followed up for 6 months, 89 (87.3%) achieved weight loss of 5% or more, 56 (54.9%) achieved weight loss of 10% or more, 24 (23.5%) achieved weight loss of 15% or more, and 8 (7.8%) achieved weight loss of 20% or more
- In November 2021, according to an article published by the National Library of Medicine, ensuring a long-term follow-up seems to be of the utmost importance for bariatric patients. Low quality follow-up in bariatric surgery is indicated as a risk factor for poor outcomes but the versatility and effectiveness of follow-up are also determinants of clinical research
- Moreover, the necessity for long-term follow-ups deters individuals from seeking treatment initially. Many prospective patients may be apprehensive about the ongoing commitment and costs associated with regular check-ins and monitoring, which is perceived as daunting or inconvenient
- This hesitancy impedes market growth, as potential consumers shy away from programs that require sustained engagement and accountability
- Consequently, the challenge of facilitating effective long-term follow-ups may limit the overall effectiveness of obesity treatments and their acceptance among the target population
Asia- Pacific Obesity Treatment Market Scope
The market is segmented on the basis of type, product type, absorption site, age group, source, delivery method, gender, and distribution channel.
|
Segmentation |
Sub-Segmentation |
|
|
|
|
|
|
|
|
Asia- Pacific Obesity Treatment Market Regional Analysis
“China is the Dominant Region in the Insulin Market for Type 1 and Type 2 Diabetes”
- China leads the Asia- Pacific obesity treatment market, driven by a high prevalence of obesity, advanced healthcare infrastructure, and strong adoption of innovative weight management solutions
- The China holds a significant market share due to the rising demand for pharmacological treatments like GLP-1 receptor agonists, bariatric surgeries, and digital weight management platforms
- In addition, increasing awareness about obesity-related health risks and the growing adoption of AI-driven weight loss programs, telehealth consultations, and non-invasive treatment solutions continue to fuel market expansion in the region
“India is Projected to Register the Highest Growth Rate”
- The India region is expected to witness the highest growth rate in the Asia- Pacific obesity treatment market, driven by increasing obesity prevalence, rising healthcare investments, and growing awareness about weight management solutions
- Countries such as India, China, and Indonesia are emerging as key markets due to shifting lifestyle patterns, rising urbanization, and an increasing number of obesity-related health complications
- India, with its expanding healthcare infrastructure and growing demand for medical weight loss treatments, remains a crucial market for obesity management. The country is witnessing increased adoption of pharmacological treatments, bariatric surgeries, and digital weight management programs
Asia- Pacific Obesity Treatment Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia- Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
The Major Market Leaders Operating in the Market Are:
- Novo Nordisk A/S (Denmark)
- Eli Lilly and Company (U.S.)
- Medtronic (U.S.)
- Boston Scientific Corporation (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Altimmune (U.S.)
- AstraZeneca (UK)
- Allurion (U.S.)
- Amgen Inc. (U.S.)
- Arena Pharmaceuticals Ltd (U.S.)
- Currax pharmaceuticals LLC (U.S.)
- COUSIN SURGERY (France)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fitterfly Healthtech Pvt. Ltd. (India)
- Morphic Medical, Inc (U.S.)
- Noom, Inc. (U.S.)
- Omada Health Inc (U.S.)
- Reshape Lifesciences Inc. (U.S.)
- Raziel (Isarel)
- Spatz FGIA Inc. (U.S.)
- Sanofi (France)
- Saniona (Denmark)
- USGI Medical (U.S.)
- VIVUS LLC. (U.S.)
- Viking Therapeutics (U.S.)
Latest Developments in Asia- Pacific Obesity Treatment Market
- In October 2024, VIVUS and UpScriptHealth have launched ChooseQ. online, a telehealth platform that offers convenient access to QSYMIA for weight management. This service allows patients to consult with healthcare providers online and receive QSYMIA directly at home. This initiative aims to improve accessibility to obesity treatment through telemedicine
- In October 2024, Zealand Pharma announced that Boehringer Ingelheim received U.S. FDA Breakthrough Therapy designation for Survodutide (BI 456906) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate or advanced fibrosis. This designation accelerates its development due to promising Phase II results
- In March 2025, Zealand Pharma announced the completion of participant enrolment in the Phase 2b ZUPREME-1 trial for Petrelintide, a long-acting amylin analog aimed at treating overweight and obesity. The trial will assess the effects of various doses of Petrelintide on body weight, safety, and tolerability over 42 weeks, with results expected in 2025
- On March 2025, Raziel Therapeutics, a pharmaceutical company focused on next-generation prescription products for the medical aesthetics market, has announced the initiation of a Phase 3 clinical study in China for RZL-012, aimed at reducing submental fat (SMF). SMF reduction is the first indication for RZL-012, with potential applications for various aesthetic fat reduction treatments in body shaping
- In October 2022, ReShape Lifesciences, a leader in weight loss and metabolic health solutions, announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) have released updated guidelines for Metabolic and Bariatric Surgery, which now include the Lap-Band. These guidelines replace the previous 30-year-old standards established by the National Institutes of Health (NIH) in 1991
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC OBESITY TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TREATMENT TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 EPIDEMIOLOGY: ASIA-PACIFIC OBESITY TREATMENT MARKET
4.4 DRUG TREATMENT RATE BY MATURED MARKETS: ASIA-PACIFIC OBESITY TREATMENT MARKET
4.5 DRUG
4.6 WORD PIPELINE
5 REGULATORY FRAMEWORK FOR THE ASIA-PACIFIC OBESITY TREATMENT MARKET
5.1 REGULATORY APPROVAL PATHWAYS
5.2 LICENSING AND REGISTRATION
5.3 REGULATORY APPROVAL PATHWAYS
5.4 LICENSING AND REGISTRATION
5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF OBESITY
6.1.2 INNOVATIONS IN ANTI-OBESITY MEDICATIONS
6.1.3 GROWTH IN BARIATRIC AND METABOLIC SURGERIES.
6.1.4 INTEGRATION OF DIGITAL HEALTH SOLUTIONS IN OBESITY TREATMENT
6.2 RESTRAINTS
6.2.1 ANTI-OBESITY DRUGS AND SURGICAL INTERVENTIONS CARRY RISKS
6.2.2 HIGH RELAPSE RATES POST-TREATMENT OF OBESITY
6.3 OPPORTUNITIES
6.3.1 INCREASING PREVALENCE OF LIFESTYLE RELATED DISEASES
6.3.2 RISING DISPOSABLE INCOME ENHANCING THE PURCHASING POWER FOR OBESITY TREATMENT RELATED PRODUCTS
6.3.3 RISE IN STRATEGIC INITIATIVES AND LAUNCHES BY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 LONG-TERM FOLLOW-UPS ASSOCIATED WITH OBESITY TREATMENT
6.4.2 ADDRESSAL OF THE LIFESTYLE AND BEHAVIORAL CHANGES
7 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS)
7.2.1 GLP-1 RECEPTOR AGONISTS
7.2.2 DUAL GIP/ GLP-1 RECEPTOR AGONISTS
7.2.2.1 Phentermine
7.2.2.2 Phentermine-Topiramate
7.2.2.3 Naltrexone-Bupropion
7.2.3 LIPASE INHIBITORS
7.2.4 DEOXYCHOLIC ACID
7.2.5 OTHERS
7.3 BARIATRIC SURGERY
7.3.1 RESTRICTIVE SURGERIES
7.3.1.1 Sleeve gastrectomy
7.3.1.2 Adjustable gastric banding
7.3.2 COMBINATION SURGERIES
7.3.2.1 Roux-en-Y gastric bypass (RYGB)
7.3.2.2 Mini-gastric bypass (MGB)
7.3.3 MALABSORPTIVE SURGERIES
7.3.3.1 Laparoscopic Surgery
7.3.3.2 Robotic-Assisted Surgery
7.3.3.3 Open Surgery
7.4 BEHAVIORAL & LIFESTYLE THERAPY
7.4.1 DIETARY INTERVENTIONS
7.4.2 BEHAVIORAL MODIFICATION THERAPY
7.4.3 PHYSICAL ACTIVITY PROGRAMS
7.4.4 PSYCHOLOGICAL COUNSELING
7.5 NON-INVASIVE/ ENDOSCOPIC PROCEDURES
7.5.1 ENDOSCOPIC SLEEVE GASTROPLASTY (ESG)
7.5.2 INTRAGASTRIC BALLOON (IGB)
7.5.2.1 Orbera intragastric balloon
7.5.2.2 Spatz adjustable balloon system
7.5.3 ASPIRATION THERAPY (ASPIREASSIST)
7.5.4 TRANSORAL GASTROPLASTY (TOGA)
7.6 MEDICAL DEVICES & TECHNOLOGIES
7.6.1 ARTIFICIAL INTELLIGENCE & DIGITAL WEIGHT MANAGEMENT PLATFORMS
7.6.2 GASTRIC ELECTRICAL STIMULATION DEVICES (MAESTRO SYSTEM)
8 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY AGE GROUP
8.1 OVERVIEW
8.2 ADULT OBESITY TREATMENT
8.3 GERIATRIC OBESITY TREATMENT
8.4 PEDIATRIC OBESITY TREATMENT
9 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 ONLINE PHARMACIES
9.3 RETAIL PHARMACIES
9.4 WEIGHT MANAGEMENT CLINICS
9.5 HOSPITAL PHARMACIES
9.6 WELLNESS & FITNESS CENTERS
10 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 CLASS III
10.3 CLASS II
10.4 CLASS I
11 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY REGION
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 JAPAN
11.1.3 INDIA
11.1.4 AUSTRALIA
11.1.5 SOUTH KOREA
11.1.6 TAIWAN
11.1.7 SINGAPORE
11.1.8 MALAYSIA
11.1.9 THAILAND
11.1.10 INDONESIA
11.1.11 PHILIPPINES
11.1.12 VIETNAM
11.1.13 REST OF ASIA-PACIFIC
12 ASIA-PACIFIC OBESITY TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 NOVO NORDISK A/S
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 ELI LILLY AND COMPANY
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT/NEWS
14.3 MEDTRONIC
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 BOSTON SCIENTIFIC CORPORATION
14.4.1 COMPANY SNAPSHOTS
14.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 JOHNSON & JOHNSON SERVICES, INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT/NEWS
14.6 ALTIMMUNE
14.6.1 COMPANY SNAPSHOT
14.6.2 PIPELINE PORTFOLIO
14.6.3 RECENT UPDATES
14.7 ASTRAZENECA
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT/NEWS
14.8 ALLURION
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
1.1.5 RECENT DEVELOPMENT/NEWS 257
14.9 AMGEN
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
1.1.13 RECENT DEVELOPMENT/NEWS 262
14.1 ARENA PHARMACEUTICALS LTD
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 CURRAX PHARMACEUTICALS LLC
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 COUSIN SURGERY
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 F. HOFFMANN-LA ROCHE LTD
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT/NEWS
14.14 FITTERFLY HEALTHTECH PVT. LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 MORPHIC MEDICAL, INC
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.16 NOOM, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 OMADA HEALTH INC
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENT
14.18 RESHAPE LIFESCIENCES
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
1.1.7 RECENT DEVELOPMENT/NEWS 281
14.19 RAZIEL
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 SPATZ FGIA INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 SANOFI
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENT
14.22 SANIONA
14.22.1 COMPANY SNAPSHOT
14.22.2 REVENUE ANALYSIS
14.22.3 PRODUCT PORTFOLIO
14.22.4 RECENT DEVELOPMENT
14.23 USGI MEDICAL
14.23.1 COMPANY SNAPSHOT
14.23.2 PRODUCT PORTFOLIO
14.23.3 RECENT DEVELOPMENT
14.24 VIVUS LLC.
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENT/NEWS
14.25 VIKING THERAPEUTICS
14.25.1 COMPANY SNAPSHOTS
14.25.2 REVENUE ANALYSIS
14.25.3 PRODUCT PORTFOLIO
14.25.4 RECENT DEVELOPMENT
14.26 ZEALAND PHARMA
14.26.1 COMPANY SNAPSHOT
14.26.2 REVENUE ANALYSIS
14.26.3 PRODUCT PORTFOLIO
14.26.4 RECENT DEVELOPMENT/NEWS
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 OBESITY PREVALENCE BY REGION (ADULTS)
TABLE 2 OBESITY PREVALENCE BY GENDER (ADULTS)
TABLE 3 OBESITY PREVALENCE BY AGE (ADULTS)
TABLE 4 ASIA-PACIFIC CLINICAL TRIAL MARKET FOR OBESITY TREATMENT
TABLE 5 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE ASIA-PACIFIC OBESITY TREATMENT MARKET
TABLE 6 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE ASIA-PACIFIC OBESITY TREATMENT MARKET
TABLE 7 ASIA-PACIFIC OBESITY STATISTICS (2022)
TABLE 8 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC ADULT OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC GERIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC PEDIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC ONLINE PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC RETAIL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC WEIGHT MANAGEMENT CLINICS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC HOSPITAL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC WELLNESS & FITNESS CENTERS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC CLASS III IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC CLASS II IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC CLASS I IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 ASIA- PACIFIC OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 39 ASIA- PACIFIC OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 ASIA- PACIFIC PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 ASIA- PACIFIC CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 ASIA- PACIFIC BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 ASIA- PACIFIC RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 ASIA- PACIFIC COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 45 ASIA- PACIFIC BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 46 ASIA- PACIFIC BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 47 ASIA- PACIFIC NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 48 ASIA- PACIFIC INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 ASIA- PACIFIC MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 ASIA- PACIFIC OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 51 ASIA- PACIFIC OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 52 ASIA- PACIFIC OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 53 CHINA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 CHINA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 CHINA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 CHINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 CHINA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 CHINA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 59 CHINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 60 CHINA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 CHINA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 CHINA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 CHINA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 CHINA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 65 CHINA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 66 CHINA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 JAPAN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 JAPAN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 JAPAN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 JAPAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 JAPAN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 72 JAPAN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 73 JAPAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 74 JAPAN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 JAPAN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 JAPAN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 JAPAN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 JAPAN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 79 JAPAN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 80 JAPAN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 INDIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 INDIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 INDIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 INDIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 INDIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 INDIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 87 INDIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 88 INDIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 INDIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 INDIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 INDIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 INDIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 93 INDIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 94 INDIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 AUSTRALIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 AUSTRALIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 AUSTRALIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 AUSTRALIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 AUSTRALIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 AUSTRALIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 101 AUSTRALIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 102 AUSTRALIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 AUSTRALIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 AUSTRALIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 AUSTRALIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 AUSTRALIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 107 AUSTRALIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 108 AUSTRALIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 SOUTH KOREA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 SOUTH KOREA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 SOUTH KOREA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 SOUTH KOREA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 SOUTH KOREA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 SOUTH KOREA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 115 SOUTH KOREA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 116 SOUTH KOREA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 SOUTH KOREA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 SOUTH KOREA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 SOUTH KOREA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 SOUTH KOREA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 121 SOUTH KOREA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 122 SOUTH KOREA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 TAIWAN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 TAIWAN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 TAIWAN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 TAIWAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 TAIWAN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 TAIWAN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 129 TAIWAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 130 TAIWAN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 131 TAIWAN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 TAIWAN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 TAIWAN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 TAIWAN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 135 TAIWAN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 136 TAIWAN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 SINGAPORE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 SINGAPORE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 SINGAPORE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 SINGAPORE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 SINGAPORE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 SINGAPORE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 143 SINGAPORE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 144 SINGAPORE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 SINGAPORE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 SINGAPORE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 SINGAPORE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 SINGAPORE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 149 SINGAPORE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 150 SINGAPORE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 MALAYSIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 MALAYSIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 MALAYSIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 MALAYSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 MALAYSIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 MALAYSIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 157 MALAYSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 158 MALAYSIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 MALAYSIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 MALAYSIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 MALAYSIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 MALAYSIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 163 MALAYSIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 164 MALAYSIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 THAILAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 THAILAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 THAILAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 THAILAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 THAILAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 THAILAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 171 THAILAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 172 THAILAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 173 THAILAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 174 THAILAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 THAILAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 THAILAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 177 THAILAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 178 THAILAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 INDONESIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 180 INDONESIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 INDONESIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 INDONESIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 183 INDONESIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 184 INDONESIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 185 INDONESIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 186 INDONESIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 187 INDONESIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 188 INDONESIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 INDONESIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 INDONESIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 191 INDONESIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 192 INDONESIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 PHILIPPINES OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 PHILIPPINES PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 PHILIPPINES CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 PHILIPPINES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 PHILIPPINES RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 PHILIPPINES COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 199 PHILIPPINES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 200 PHILIPPINES BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 PHILIPPINES NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 PHILIPPINES INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 PHILIPPINES MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 PHILIPPINES OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 205 PHILIPPINES OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 206 PHILIPPINES OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 VIETNAM OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 VIETNAM PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 VIETNAM CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 VIETNAM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 VIETNAM RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 212 VIETNAM COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 213 VIETNAM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 214 VIETNAM BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 VIETNAM NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 VIETNAM INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 VIETNAM MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 VIETNAM OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 219 VIETNAM OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 220 VIETNAM OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 REST OF ASIA-PACIFIC OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 ASIA-PACIFIC OBESITY TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC OBESITY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC OBESITY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC OBESITY TREATMENT MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC OBESITY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC OBESITY TREATMENT MARKET: LIFELINE CURVE
FIGURE 7 ASIA-PACIFIC OBESITY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC OBESITY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC OBESITY TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 ASIA-PACIFIC OBESITY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA-PACIFIC OBESITY TREATMENT MARKET: SEGMENTATION
FIGURE 12 ASIA-PACIFIC OBESITY TREATMENT MARKET EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 FIVE SEGMENTS COMPRISE THE ASIA-PACIFIC OBESITY TREATMENT MARKET , BY TREATMENT TYPE
FIGURE 15 RISING PREVALENCE OF OBESITY IS EXPECTED TO DRIVE THE GROWTH OF ASIA-PACIFIC OBESITY TREATMENT MARKET FROM 2025 TO 2032
FIGURE 16 THE PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC OBESITY TREATMENT MARKET IN 2025 - 2032
FIGURE 17 MARKET OVERVIEW
FIGURE 18 PREVALENCE OF OBESITY IN ADULTS AGE 20 AND OLDER, BY SEX AND AGE: UNITED STATES, AUGUST 2021–AUGUST 2023 SOURCE: CENTERS FOR DISEASE CONTROL AND PREVENTION.
FIGURE 19 SHARE OF PRE-OBESE AND OBESE PERSONS AGED 16 YEARS OR OVER, BY SEX, 2022 (%)
FIGURE 20 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2024
FIGURE 21 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 22 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)
FIGURE 23 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY AGE GROUP, 2024
FIGURE 25 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY AGE GROUP, 2025-2032 (USD THOUSAND)
FIGURE 26 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY AGE GROUP, CAGR (2025-2032)
FIGURE 27 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 29 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 30 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 31 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2024
FIGURE 33 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 34 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY PATIENT TYPE, CAGR (2025-2032)
FIGURE 35 ASIA-PACIFIC OBESITY TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC OBESITY TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 37 ASIA-PACIFIC OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
